SkinBioTherapeutics plc, a life science company focused on skin health, announces the commencement of the third and final phases of its human study and provides a summary of key scientific and commercial milestones achieved so far in 2018.
The final phase of the study seeks to ensure that the original SkinBiotix® technology retains the same beneficial property to improve skin barrier health when in a cream formulation. The Company is pleased to announce that the first of its 120 volunteers commenced testing last week. Provisional results for some of the volunteers are expected to be available for analysis at the end of December with the full read out on all 120 volunteers expected during Q1 2019.
The results of this final phase will complete the data pack to share with potential global partners interested in commercialising the SkinBiotix® technology in the cosmetic skin care market.
See the announcement in full at SkinBioTherapeutics.com